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CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
Introduction 
 The development of antimicrobial resistance by bacterial pathogens is a global crisis of 
increasing importance [1]. Scientists now recognize that each new antibiotic produced has a 
limited lifespan and therefore new anti-infective agents are constantly in demand. Throughout 
history, cultures have relied heavily on plants for their therapeutic properties. Many of the plants 
used in traditional medicine are still in use to this day [2]. Reports have estimated that plants 
have contributed to the development of at least half of current pharmaceuticals [3]. However, 
few of these are used as antimicrobials, and the vast majority are from bacterial and fungal 
sources [2]. This has prompted the scientific community to search for phytochemicals which can 
be used to develop pharmacetucal treatments for disease and illness-causing bacterial pathogens. 
With an estimated 250,000 to 500,000 plant species on earth, plant based antimicrobials 
represent a vast untapped reservoir with great pharmaceutical potential [2]. Furthermore, marine 
organisms account for about half of the worlds biodiversity and have been identified as an 
invaluable source of bioactive compounds as well. Although numerous marine organisms and 
sponges have been found to exhibit antimicrobial behaviour, antimicrobial activity of many 
marine organisms has yet to be explored [4]. The isolation and characterization of natural 
antimicrobials from plant and marine sources may lead to the development of antimicrobial 
agents to help control antimicrobial-resistant pathogens.  
Antimicrobial Resistance 
 Antibiotic therapy is often the initial action taken against microbial infections in humans 
although a positive correlation is known to exist between antibiotic use and antimicrobial 
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resistance development [5]. Furthermore, the incidence of antimicrobial resistance in food-
poisoning bacteria has also increased, partly due to the excessive use of antibiotic therapy in 
healthy livestock [6]. There is significant public demand for reformed prescribing practices by 
physicians and the cessation of unnecessary feeding of  low levels of antibiotic to healthy food-
producing animals [6]. Although informed physcians have improved prescribing practices, 
economic gain represents a strong motivator to farmers to continue to over-use antibiotics. 
Resistance in common pathogens has now made some of the most effective and reliable 
antimicrobial agents obsolete [1]. Of particular concern are those organisms which have 
developed resistance to several classes of antibiotics. Infections which were once easily cured 
may now require several courses of antibiotics and treatment may take months or years. In the 
past, pharmacetucial coprorations were consistently producing new, more potent antimicrobial 
agents in order to compete with the development of antimicrobial resistance. Although the need 
for new antimicrobials is apparent, pharmaceutical corporations are no longer developing 
sufficient amounts of novel antimicrobials and bacterial strains have developed resistance to 
even the newest antibiotics [7]. It is clear that without safe, effective alternatives readily 
available, antimicrobial resistance has the potential to hinder our ability to treat serious infections 
[5].  
Relevant Bacterial Species 
There are a number of bacterial species that are currently regarded as high priority 
pathogens based on antimicrobial resistance development, high incidence of infection, or a 
combination of both. Several bacterial species account for the majority of the cases of food borne 
illness and outbreaks. Bacillus subtilis is widespread in the environment, and can cause food 
spoilage and food borne illness even after cooking due to its ability to form spores [8]. 
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Campylobacter jejuni is the leading cause of food borne bacterial gastroenteritis worldwide [9]. 
Clostridium perfringens food poisoning ranks among the most common foodborne illnesses 
worldwide [10]. Escherichia coli 0157 H:7 is responsible for many food and water borne 
outbreaks of diarrhea and hemorrhagic colitis worldwide [11].  Listeria Monocytogenes is a 
ubiquitous pathogen that is responsible for food borne outbreaks, often affecting 
immunocompromised individuals, pregnant women and newborns [12]. Salmonella enterica 
serovar typhimurium is a common cause of bacterial enterocolitis. Furthermore, testing has 
shown that an increasing proportion of isolates of Salmonella enterica are now resistant to 
several antimicrobial agents [13].  
 There are also a number of bacterial pathogens which contribute to many of the cases of 
bacterial infections in humans. Strains of the pathogenic bacteria Acinetobacter baumanii have 
been reported to be resistant to all known antibiotics [14]. Clostridium difficile is a bacterial 
species often associated with hospital outbreaks, due to the prevalent use of broad-spectrum 
antibiotics. One fluoroquinolone-resistant strain has been identified as the cause of numerous 
outbreaks of severe C. difficile infection [15]. Carbapenem  reisitant strains of Klebsiella 
pneumoniae;  a major cause of nosocomial infections, have left few treatment options for the 
infection [16]. Treatment of infections caused by the pathogenic bacteria Pseudomonas 
Aeruginosa is becoming more difficult due to its rapidly developing resistance to multiple 
classes of antibiotics [17]. Methycillin-resistant Staphylococcus areus (MRSA) infections are a 
major cause of hospital-acquired infections, and is now considered an epidemic in many US 
hospitals and long term care facilities [18].  Streptococcus pneumoniae is a human pathogen 
currently exhibiting fluoroquinolone resistance and representing a major cause of morbidity and 
mortality worldwide via diseases such as pneumonia, meningitis, and bacteraemia [19]. These 
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twelve bacterial species pose a significant risk to the public and intervention is currently required 
to regain control over these common pathogens.  
Natural Products in Drug Discovery 
 With the increase in bacterial resistance to conventional treatments, there is also an 
increasing interest in plant-derived antimicrobial compounds. The screening of natural sources 
has been key in the discovery of many classes of drugs. Natural products, including both extracts 
as well as pure compounds have unlimited potential as new drug leads due to their tremendous 
chemical diversity [20].  Plant and marine sources have been found to be a limitless source of 
bioactive compounds [4]. The distribution of plant compounds is commonplace in natural food 
stores, and consumer demand for alternative treatments is increasing [2]. There was a reported 
37% increase in the sale of plant derived medicines between the years 1995 to 1996 [21]. 
Unfortunately, the purity of these substances is unreliable and there is limited information 
available regarding dosage. Many scientists believe that natural antimicrobials may eventually 
replace traditional approaches of controlling pathogens [22]. The reasons to further develop 
natural products are numerous and include the high cost of currently available synthetic 
medicines, adverse side-effects of pharmaceuticals, and the public perception of gentleness of 
natural medicines. 
 The traditional method of compound isolation and characterization has long been used 
by pharmaceutical companies for natural product development. However, the process eventually 
acquired as reputation for being expensive, repetitive, tedious, and time consuming, causing 
pharmaceutical companies to draw back on these research approaches in the 1990’s and early 
2000’s. At this time a new method was developed which relied on combinatorial chemistry and 
large compound libraries. The success of this method has been limited, which is proven by the 
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fact that only one combinatorial new entity has been approved by the FDA since the 1980’s [23]. 
The public has relied on plants for new lead compounds in the initial stages of pharmaceutical 
development, and the combinatorial chemistry approach has not yet shown to be productive. It is 
unclear as to whether or not pharmaceutical companies and researchers will revert to the 
traditional method of isolation and characterization to increase the amount of new 
pharmaceuticals introduced to the market. It is important to note, however, that there have been 
numerous technological advances making the traditional method a more viable option. These 
include more sensitive instruments and more available NMR/MS data.  
Natural Products as Antimicrobials 
 Natural products have been significant in antibiotic drug discovery with most antibiotics 
being derived from a natural product or a natural product lead [24]. Reports estimate that 60% of 
commercially available anti-infective agents are of natural product origin [3, 25]. Plants produce 
both primary and secondary metabolites. Those metabolites responsible for their defense 
mechanism fall under the latter category. Secondary metabolites are produced by plants for the 
purpose of protection against predators as well as infections [26]. Secondary metabolites such as 
phenolics, terpenoids, alkaloids, and flavonoids have known antimicrobial properties [2]. 
Similarly, marine sponges have developed chemical defenses to protect against the colonization 
of pathogenic bacteria [27]. For this reason, the antimicrobial activity of marine sponges has 
been studied in an attempt to harness the sponges natural potency [28-30]. Marine sources have 
been found to be an invaluable source of bioactive compounds [4].  
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Natural Products in Food Safety 
 Characterization of bioactive properties of plant extracts has potential application, not 
only in pharmaceuticals, but in agriculture and food preservation as well [31-33]. Currently, the 
most common application of natural antimicrobials is the direct addition of antimicrobial 
compounds to food [34]. Microorganisms can cause off flavor, odor, color, sensory, and textural 
properties in foods. Furthermore, microorganisms in food can cause food-borne illness [35]. 
Consumer concern regarding synthetic chemical additives has made foods preserved with natural 
additives the more popular choice [34]. For this reason, scientists have expanded their efforts to 
discover natural compounds that can prevent or inhibit the growth of microorganisms in food. 
Some natural antimicrobials are now used industrially in the processing of food. Foods are often 
dipped, sprayed, or coated with active solutions prior to packaging. This type of application of 
natural antimicrobial compounds is now utilized on a variety of foods including meat, fish, dairy 
products, minimally processed fruit and vegetables, and cereal-based products [34].  
 In this study, the antimicrobial activity of a number of plant and marine extracts is 
investigated. A number of extracts are chosen and the active compound(s) isolated and 
identified. The compounds are thoroughly investigated using a variety of techniques intended to 
evaluate each compound’s antimicrobial activity level, stability, safety, and overall potential for 
use as a natural antimicrobial.  
 
 
 
  
7 
 
 
CHAPTER 2: ISOLATION AND IDENTIFICATION OF COMPOUNDS FROM 
PLANTAND MARINE ORGANISMS WITH ANTIMICROBIAL ACTIVITY  
Screening of Plant and Marine Organisms 
Introduction 
 The natural products repository of the National Cancer Institute (NCI) through the U.S. 
National Institutes of Health (NIH) has collected close to 17,000 extracts of plant and marine 
organisms.  Extracts were provided by the National Cancer Institute (NCI) to allow for this 
research to take place. Initial screening of antibacterial compounds from plants is commonly 
performed on crude extracts in order to identify ‘hits’, which are selected based on their desired 
bioactivity. In order to identify antimicrobial agents, the most commonly used screening method 
is known as broth microdilution [36]. This method allows for the testing of multiple samples at 
once. Although the this method is used numerous times throughout this work, at the initial 
screening stage, the method was simplified in order to test hundreds of plant and marine extracts 
at a single concentration, which could be repeated to test a number of different bacterial species.  
Materials and Methods 
 Bacterial species- Seven high priority pathogens were used to fulfill this aim. Bacterial 
reference strains were obtained from the American Type Culture Collections (ATCC, 
Mannassas, VA).  The bacterial strains included were: A. baumannii, ATCC 19606; C. jejuni, 
ATCC 33291; C. difficile, ATCC 9689; C. Perfringens, ATCC 13124;  K. pneumoniae, ATCC 
13883; S. pneumoniae, ATCC 49136; and P. Aeruginosa, ATCC 27853. 
 Plant and marine extracts- A total of 106 extracts of plant and marine organisms 
obtained from the natural products repository of NCI were identified through preliminary 
experiments on thousands of extracts which were chosen based on their inhibitory activity on E. 
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coli 0157 H:7 bacteria. Each extract was prepared by the Natural Products Extraction Laboratory 
by extracting each organism with a 1:1 mixture of dichloromethane and methanol and then with 
water. Each extract was stored at -20 ˚C. 
 Antimicrobial screening- A simplified version of the broth microdilution method 
described by the Clincal and Laboratory Standards Institute (CLSI) guidelines was utilized for 
the purpose of screening the extracts [37, 38]. Brain heart infusion broth (BHI), thioglycollate 
broth, nutrient broth, and cation-adjusted mueller hinton broth (CAMHB) were used for the 
growth medium. Each plant extract, was dissolved in dimethyl sulfoxide (DMSO) to produce a 
stock solution with the concentration of 1 mg/ml. This was further diluted in sterile distilled 
water to prepare test solutions with a concentration of 50 µg/ml. Overnight bacterial broth 
suspension was diluted 20x in an appropriate broth. Assay plates were prepared to contain 
extracts at a single concentration; A. baumannii; 10 µg/ml, C. jejuni; 5 µg/ml, C. difficile 5 
µg/ml; C. Perfringens; 5 µg/ml,  K. pneumoniae; 5 µg/ml, S. pneumoniae; 5 µg/ml, and P. 
Aeruginosa; 20 µg/ml.  Assay plates were incubated in appropriate conditions (aerobic, 
anaerobic, or microaerophilic) at 37 ºC for 24 h, and growth or no-growth was assessed by the 
naked eye through comparison with controls. DMSO dilutions in sterile distilled water (1:19 
ratio DMSO to water) that did not contain any test material and a blank containing no bacteria 
were included as controls.  
Results 
 Screening of 106 plant and marine organism extracts led to the identification of 4 
extracts with superior antimicrobial activity. The majority of the extracts tested had limited 
antimicrobial activity; inhibiting the growth of only one or none of the tested microorganisms. 
The extracts showing the greatest antimicrobial activity inhibited the growth of a minimum of 3 
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bacterial species. These extracts were N014267 from Mammea africana, C025163 from 
Phyllospongia papyracea, C022687 from Monanchora unguiculata, and C022615 from Dysidea 
herbacea (Tables 1a-c). These 4 extracts demonstrated activity against a broad spectrum of 
bacterial species. The M. africana extract inhibited the growth of C. difficile, C. jejuni, and S. 
Pneumonoiae at a concentration of 5 µg/ml. The P. papyracea extract also inhibited the growth 
of C. difficile, C. jejuni, and S. Pneumonoiae at a concentration of 5 µg/ml.  Monanchora 
unguiculata is especially noteworthy as this extract showed inhibitory activity on every bacterial 
species included in the screening. Furthermore the M. unguiculata extract was the only extract of 
the 106 initial extracts to exhibit inhibitory activity on the bacterial species A. baumani and P. 
aeruginosa. Finally, the D. herbacea extract inhibited the growth of C. difficile, C. jejuni, C. 
perfringens, and S. pneumoniae at a concentration of 5 µg/ml. Based on the results of the initial 
screening, these 4 extracts were chosen for further study as they showed the strongest, broad-
spectrum antimicrobial activity.  
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Table 1a Antimicrobial activity of extracts numbered 1-40 on bacterial species.  
 
 
+ Represents inhibition of bacterial growth at the specified concentration by comparison of 
turbidity with a Blank assessed by the naked eye following 24 hr incubation period.  
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Table 1b Antimicrobial activity of extracts numbered 41-80 on bacterial species. 
 
 
 
+ Represents inhibition of bacterial growth at the specified concentration by comparison of 
turbidity with a Blank assessed by the naked eye following 24 hr incubation period.  
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Table 1c Antimicrobial activity of extracts numbered 81-106 on bacterial species. 
 
+ Represents inhibition of bacterial growth at the specified concentration by comparison of 
turbidity with a Blank assessed by the naked eye following 24 hr incubation period.  
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  Discussion 
 The first extract chosen for its significant inhibitory activity was from Mammea 
africana. M. africana  (Family Clusiaceae) is widely distributed in tropical Africa. The stem bark 
of the plant is commonly used in traditional medicine for the treatment of malaria related fever, 
internal heat, microbial infections, stomach pains, scabies and other skin diseases, rheumatic pain 
and fybromyoma [39-41]. Mammea coumarins have been isolated and identified from a variety 
of plant species including Mammea africana and other species of Mammea, Mesua, and 
Calophyllum [33]. Mammea coumarins have been found to express a wide range of bioactivities, 
including antibacterial [42, 43], antifungal [44], antioxidant [45], insecticidal [46], anticancer 
[39, 45, 47], and anti-HIV [48]. 
 A second extract which was identified through screening was from Phyllospongia 
Papyracea. P. Papyracea ( Family Thorectidae) is a marine sponge of the Dictyoceratida order. 
Two types of molecular structures have been recorded as discovered from Phyllospongia, 
scalarane sesterpenes and polybrominated biphenyl ethers [49]. While much research has been 
conducted on the former, the bioactivity of the latter is less well known [49]. Bromophenolic 
compounds are present in high concentrations in marine sponges and have been found to show 
antibacterial [50], antifungal [51], and anti-inflammatory activities [52] as well as cytotoxicity 
[25, 50, 53].  
 The extract from Monanchora unguiculata was chosen as it was shown to possess 
inhibitory activity on all of the bacterial species included in the screening.  M. unguiculata 
(Family Crambeidae) is a marine sponge with distribution in the Indian Ocean. Investigation of 
the sponge M. unguiculata has previously led to the identification of pentacyclic guanidine 
alkaloids [54]. The cyclic guanidine derivatives have previously been shown to possess a broad 
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range of bioactivity. This class of metabolites has shown antifungal, antiviral, antiprotozoal, and 
antimicrobial activities. Furthermore, these compounds have also been found to exhibit 
cytotoxic, antimalarial, and anti-HIV activity [55, 56]. The guanidine alkaloids group includes 
ptilomycin A, the cramescins, crambescidins, ptilocaulins, mirabilines, and the batzelladines, 
which have similar structural features and biological activities. The members of this class include 
the pentacyclic and tricyclic guanidine alkaloids which bear the (5,6,8b)- 
triazaperhydroacenaphthalene skeleton [57]. Increasing interest in this group of compounds has 
led researchers to begin studies to synthesize such compounds [58]. 
 The final extract that was chosen for further study was obtained from the sponge 
Dysidea herbacea (Family Dysideidae). D. herbacea is a tropical marine sponge which has been 
collected from the waters off the shore of Australia and Indonesia [59]. This sponge has two 
known chemotypes. The first produces sesquiterpenes and polychlorinated amino acid 
derivatives, while the other produces only polybrominated diphenyl ethers [60]. It has been 
suggested that the production of polybrominated diphenyl ethers is due to a cyanobacterium, 
Oscillatoria spongeliae, and not the sponge itself. The compounds are thought to offer a mode of 
protection to the sponge from predators and bacterial invasion [61]. The polybrominated 
diphenyl ethers have been found to exhibit a range of notable activities. They have been found to 
exhibit antibacterial activities on S. aureus and T. Mentagrophytes, as well as inhibition of a 
number of tumor-promoting enzymes [60, 62]. 
 Previous work pertaining to these four species is far from complete. Although it is 
known that they all possess bioactive compounds, none of these species has previously been 
tested for antimicrobial activity on a broad range of bacterial pathogens.  
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Isolation of Active Compounds 
Introduction 
 Natural product research often follows a number of steps intended to best utilize the 
biologically active compounds of plant resources. These steps are extraction, pharmacological 
screening, isolation and characterization of bioactive compounds, toxicological evaluation, and 
finally clinical evaluation. [63]. There are numerous potential setbacks involved in this type of 
research. Fractionation of extracts can lead to a reduction or loss of biological activity by 
compound break-down or loss of additive or synergistic effects between other active compounds 
present in the extract. Furthermore, there is no one standardized separation technique for extracts 
and when an active compound is isolated, it is often not possible to re-isolate even when 
following an identical protocol [20]. In this regard, a systematic approach to extraction and 
isolation of compounds was of the utmost importance in obtaining pure antimicrobial 
compounds.  
 Each extract is a complex combination of bioactive compounds and phytochemicals with 
different characteristics. For this reason, separation poses a challenge, often involving numerous 
steps and a variety of fractionation techniques [63]. Bioassay is necessary between each step to 
identify the active fraction/fractions. When an active fraction was identified, a separation plan 
was made based on the characteristics of the compounds which were deduced from the previous 
separation, ex. polarity, size of molecule, etc.  
Materials and Methods  
  Isolation of Active Compounds - Each extract was fractionated individually as described 
in the following paragraphs. A combination of multiple purification techniques including liquid-
liquid extraction, open column chromatography, Sephadex cartridge, high performance liquid 
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chromatography (HPLC) was utilized. Solvents were removed using evaporation or sublimation, 
to determine the final amount obtained for each sample. Samples were dissolved and diluted to 
100 µg/ml in an appropriate solvent. A bioassay guided approach to fractionation was taken; in 
which, the activity of fractions was assessed at each stage of fractionation via the simplified 
microbroth dilution method previously described using a bacterial strain proven to be inhibited 
by the extract in the screening. Fractions showing inhibitory activity were subject to additional 
fractionation. Thin layer chromatography (TLC) and high performance liquid chromatography 
(HPLC) were used to determine the point in the separation process when a single pure active 
compound has been isolated. 
  Fractionation and isolation of compound 1 from Mammea africana - Crude extract from 
the bark of the M. africana was partitioned by liquid-liquid extraction using hexane, ethyl 
acetate, butanol, and water. Active fractions were identified through an antibacterial activity 
assay.  The assay revealed the hexane and ethyl acetate fractions exhibited antimicrobial activity. 
These two fractions were combined and subjected to fractionation via open column 
chromatography. The chromatography was carried out on 100 g of silica gel (40-60 μm, Acros, 
NJ) in a glass column (457×40 mm) and eluted with hexane, acetone, and methanol to yield a 
total of 13 fractions. Fraction 5 and 6 were identified as containing the active compound. HPLC 
with a reversed-phase C-18 column (150 x 4.6 mm) by a Hitachi DAD L-2455 detector was used 
to verify that a single compound was present in Fraction 5 (Scheme 1).  
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Scheme 1 Flow chart depicting the bioactivity-driven fractionation of Mammea africana extract.  
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  Fractionation and isolation of compound 2 from Phyllospongia papyracea - Crude 
extract from P. papyracea was partitioned by liquid-liquid extraction using hexane, ethyl acetate, 
n-butanol, and sterile distilled water. Bioactivity assay revealed the hexane and ethyl acetate 
fractions exhibited antimicrobial activity. These two fractions were combined and subjected to 
fractionation via open column chromatography. The chromatography was carried out on 100 g of 
silica gel (40-60 μm, Acros, NJ) in a glass column (457×40 mm) and eluted with hexane, 
acetone, and methanol to yield a total of 15 fractions. Fractions were monitored on TLC Silica 
Gel 60 F254 (EMD, Gibbstown, NJ) and visualized under UV (254 nm and 365 nm) and 10% 
H2SO4 (in EtOH). Fraction 3,4 and 5 were identified as active fractions and were analyzed with 
high performance liquid chromatography (HPLC) on a reverse phase C18 column (150 x 4.6 
mm) by a Hitachi DAD L-2455 detector to determine whether a single compound was present. 
UV-VIS spectrum was recorded in methanol/H2O using a Hitachi DAD L-2455 (Scheme 2).  
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Scheme 2 Flow chart depicting the bioactivity-driven fractionation of Phylospongia papyracea 
extract.  
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  Fractionation and isolation of compound 3 from Monanchora unguiculata - Crude 
extract from M. unguiculata was partitioned by liquid-liquid extraction using ethyl acetate, 
butanol, and water. Active fractions were identified through an antibacterial activity assay.  The 
assay revealed the butanol fraction exhibited antimicrobial activity. This fraction was subjected 
to fractionation via XAD column chromatography using the solvents water, ethanol, and finally 
acetone. Following bioassay, the ethanol fraction was found to contain the active compound. 
This fraction was further separated using OASIS cartridge chromatography and sterile distilled 
water as the solvent. Fraction 2-2 was found to be active, and HPLC was used to further purify 
the fraction using a reversed-phase C-18 column (150 x 4.6 mm) by a Hitachi DAD L-2455 
detector. The first peak was collected and was analysed using HPLC to determine that it 
contained a purified substance (Scheme 3).   
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Scheme 3 Flow chart depicting the bioactivity-driven fractionation of Monanchora unguiculata 
extract.  
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  Fractionation and isolation of compound 4 from Dysidea herbacea - Crude methanol 
extract from D. herbacea was partitioned via open column chromatography. The 
chromatography was carried out on 100 g of silica gel (40-60 μm, Acros, NJ) in a glass column 
(457×40 mm) and eluted with hexane, acetone, and methanol to yield a total of 12 fractions. 
Fraction 2 was identified via bioassay to contain the active fraction. It was filtered using 
Whatman No. 2 filter paper to separate the precipitate. The precipitate was then subjected to a 
Sephadex column. The first fraction to elute was active.  HPLC was used to further purify the 
fraction using a reversed phase C-18 column (150 x 4.6 mm) by a Hitachi DAD L-2455 detector. 
The second peak was collected and was analysed using HPLC to determine that it contained a 
purified substance (Scheme 4).   
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Scheme 4 Flow chart depicting the bioactivity-driven fractionation of Dysidea herbacea extract.  
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Results 
Extracts were fractionated individually as described following the outline depicted in 
Schemes 1-4. Each time a sample was fractionated; all fractions were included in a simplified 
microbroth dilution assay to identify the active fraction or fractions. In this way, the active 
fraction was purified as the inactive fractions were removed. HPLC was used to determine the 
presence of a single compound. If a fraction led to an HPLC chromatogram displaying a single 
peak, fractionation was discontinued and further identification was initiated (Figure 1-4). The 
chromatograms obtained through HPLC analysis of the isolated product from the four active 
extracts each display a prominent single peak. The final fractions, assumed to be single 
compounds, were named as follows: Compound 1, isolated from crude M. africana extract, 
Compound 2, isolated from crude P. papyracea extract, Compound 3 isolated from crude M. 
unguiculata extract, and Compound 4, isolated from crude D. herbacea extract.  
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Figure 1 HPLC chromatogram of compound 1 isolated from Mammea africana using a 90% 
methanol isocratic method.  
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Figure 2 HPLC chromatogram of compound 2 isolated from Phyllospongia papyracea using an 
isocratic 90% methanol method.  
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Figure 3 HPLC Chromatogram of compound 3 isolated from Monanchora unguiculata using an 
isocratic 100% methanol method. 
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Figure 4 HPLC chromatogram of compound 4 isolated from Dysidea herbacea using an 
isocratic 100% methanol method.   
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Discussion 
 
  The goal of fractionation is to isolate the active compound in the extract by 
systematically removing the components which do not contribute to its bioactivity of interest. 
HPLC is often the final analytical tool used. In this case, active fractions which were believed to 
contain a single compound were analyzed by reversed-phase HPLC using an isocratic methanol-
based method. A single peak is observed when a compound passes through the detector and 
absorbs UV light. When the HPLC chromatogram displayed a single peak, fractionation was 
discontinued and characterization studies were initiated. In this case, a single peak in an HPLC 
chromatogram was the signal that the active compound had been isolated. Figure 3 shows a 
number of peaks with retention time under 3 minutes. It is common to see a number of peaks 
appear on the chromatogram within the first 5 minutes and these peaks are usually associated 
with solvent being detected and are not necessarily attributed to multiple compounds present in 
the system being analyzed.       
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Identification of Active Compounds 
Introduction  
Combinatorial chemistry is often employed in determination of chemical identity and 
molecular formulae of unknown compounds. Confirmation relies on verification of information 
by comparison of liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic 
resonance (NMR) data. Integration of MS and NMR spectral data is the method of choice for 
structure verification [64].  
Materials and Methods 
  Characterization of Active Compounds - Nuclear magnetic resonance spectroscopy 
(NMR) in combination with mass spectrometry (MS) was performed in the Chemistry 
Department at Wayne State University. Chromatograms were analyzed by the post-doctoral 
researcher, Dr. Sun. Through analysis of chromatograms and comparison with data previously 
reported in the literature, the chemical structure of the compounds was determined. 
Characterization of compound 1 from Mammea africana - The compound was analyzed on a 
Waters LCT Premier high resolution exact mass spectrometer and Waters ZQ2000 single 
quadrupole mass spectrometer (Waters Corp., Milford, Massachusetts).  NMR spectra (
1
H, 
13
C, 
DEPT) were recorded on a Varian Mercury 400 MHz instrument (Varian, Inc., Palo Alto, 
California). 
1
H and 
13
C were observed at 400.13 and 100.03 MHz using DMSO-d6 as the 
solvent.   
  Characterization of compound 2 from Phyllospongia papyracea: The compound was 
analyzed on a Waters LCT Premier high resolution exact mass spectrometer (Waters Corp., 
Milford, Massachusetts).  The mass spectrometer was operated in negative electrospray 
ionization at a temperature of 350º C and a voltage of 4 kV.  Mass scan spectra were measured 
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from 100 m/z up to 1400 m/z at 1000 amu/second. NMR spectra (
1
H, 
13
C, DEPT) were recorded 
on a Varian Mercury 400 MHz instrument (Varian, Inc., Palo Alto, California). NMR spectra (
1
H 
and 
13
C) were observed at 400.13 and 100.03 MHz using DMSO-d6 as the solvent.  Mass spectra 
were obtained on a QSTAR XL MS/MS system.  
   Characterization of compound 3 from Monanchora unguiculata: NMR spectra were 
obtained with Varian VNMRS-500 MHz (500 MHz, 
1
H;125 MHz, 
13
C) and Agilent DD2-600 
MHz (600 MHz, 
1
H;150 MHz, 
13
C) spectrometers; chemical shifts (δ) are reported in ppm 
referenced to the solvent peak. The compound was analyzed on a Waters LCT Premier high 
resolution exact mass spectrometer (Waters Corp., Milford, Massachusetts), EIMS on a VG 70-
250-S mass spectrometer (Micromass Corp., Manchester UK) . Optical rotations were taken on a 
Perkin-Elmer 341 polarimeter.  
  Characterization of compound 4 from Dysidea herbacea: The compound was analyzed 
on a Waters LCT Premier high resolution exact mass spectrometer and Waters ZQ2000 single 
quadrupole mass spectrometer (Waters Corp., Milford, Massachusetts).  NMR spectra (
1
H, 
13
C, 
DEPT) were recorded on a Varian Mercury 400 MHz instrument (Varian, Inc., Palo Alto, 
California). 
1
H and 
13
C were observed at 400.13 and 100.03 MHz using DMSO-d6 as the 
solvent.   
 Results 
  Characterization of compound 1 from Mammea africana - Fractionation of the 
traditional medicinal plant Mammea africana yielded a known coumarin with antimicrobial 
activity. The active compound, appearing as yellow crystals was analyzed using 
1
H and 
13
C 
NMR (Table 2).  Its 
1
H NMR spectrum showed one olefinic proton singlet at 5.93 characteristic 
of H-3 of a 4-substituted coumarin. 
1H NMR spectrum δ 7.39 (2H, dd, J=7.0, 3.5 Hz), 7.52 (2H, 
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dd, J=7.0, 3.5 Hz), and 7.51 (1H, t, J=7.0 Hz), and 
13
C NMR spectrum 137.21, 127.39, 129.14, 
and 129.72 indicated the presence of one phenyl group. δ 3.55 (2H, d, J=8.0 Hz), 5.26 (1H, t, 
J=8.0 Hz), 1.86 (3H, s), and 1.74 (3H, s) and δ 21.65, 120.59, 135.4, 25.8, and 18.0 showed one-
substituted prenyl group. δ2.85 (1H, d, J=8.0), 2.17 (1H, m), 0.89 (6H, d, J=8.0Hz) and δ207.1, 
53.6, 24.7, 22.7, and 22.7 indicated the presence of one isovaleryl group. Two phenolic hydroxyl 
signals were at δ 11.0 and 9.9 in 1H NMR, too. Comparison of its 1H and 13C NMR spectra with 
those previously reported in the literature allowed this active compound to be identified as 
mammea A/AA [65]. The structure of mammea A/AA is illustrated in (Figure 5).  
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Table 2 
1
H and 
13
C NMR spectral data of compound 1 isolated from Mammea africana. 
 
Position δC δH 
2 159.5 s  
3 112.7 d 5.931, s 
4 154.4 s  
4a 100.8 s  
5 159.5 s  
6 107.2 s  
7 163.2 s  
8 108.0  
8a 156.6 s  
1' 137.2 s  
2', 6' 127.4d 7.39, dd, J=3.5, 7.0 
3', 5' 129.1 d 7.52, dd, J=3.5, 7.0 
4' 129.7 d 7.51, t, J=7.0 
1'' 207.1 s  
2'' 53.6 t 2.85, d, J=8.0 
3'' 24.7 d 2.17, m 
4'', 5'' 22.7q 0.89, d, J=8.0 
1''' 21.7t 3.55, d, J=8.0 
2''' 120.6d 5.26, t, J=8.0 
3''' 135.4 s  
4''' 25.8 q 1.86, s 
5''' 18.0 q 1.74, s 
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Figure 5 Chemical structure of compound 1; Mammea A/AA isolated from Mammea africana. 
 
 
 
The structure of the active compound was determined to be 4-phenyl-5,7-dihydroxy-6-(3-
methylbutanoyl)-8-(3-methyl-2-butenyl)-2H-1-benzopyran-2-one, known as mammea A/AA. 
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  Characterization of compound 2 isolated from Phyllospongia papyracea - Fractionation 
of the sponge Pyllospongia papyracea yielded a known tetrabrominated diphenyl ether with 
antimicrobial activity. The active compound, appearing as a white powder was analyzed using 
1
H and 
13
C NMR.  The compound was identified as 4,6-Dibromo-2-(4,6-dibromo-2-
hydroxyphenol) anisole (CAS80246-35-1) (Figure 10) . 1H NMR (CDCl3, 400 MHz) δ 7.34 (d, 
J= 2.4Hz, H-5′), 7.43(d, J= 2.4Hz, H-5), 7.17(d, J= 2.4Hz, H-3′), 6.77 (d, J= 2.4Hz, H-3), 4.03 (s, 
OCH3); 
13C NMR (CDCl3, 125.7 MHz) δ 150.9 (C-2), 150.4 (C-2′), 145.6 (C-1), 138.7 (C-1′), 
130.4 (C-5), 127.4 (C-5'), 120.2 (C-3'), 119.9 (C-4'), 119.0 (C-6), 118.5 (C-3), 117.4 (C-4), 117.3 
(C-6′), 61.6 (OCH3); ESIMS [M - H]- m/z 526.712 (15), 528.7144 (83), 530.7039 (100), 
532.7091 (77), 534.7084 (20), 534.7549 (5). These spectral data were in agreement with those 
previously reported in the literature [53, 66].  
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Table 3 
1
H and 
13
C NMR spectral data of compound 2 isolated from Phyllospongia papyracea. 
 
Position 
1
H 
13
C 
1  145.6  
2  150.9  
3 6.77 (d, J= 2.4, H-3), 118.5  
4  117.4  
5 7.43(d, J= 2.4, H-5), 130.4  
6  119.0  
1′  138.7  
2′  150.4  
3′ 7.17(d, J= 2.4, H-3′), 120.2  
4′  119.9  
5′ 7.34 (d, J= 2.4, H-5′),  127.4  
6′  117.3  
OCH3 4.03 (s) 61.6  
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Figure 6 Chemical structure of compound 2; a tetrabominated diphenyl ether isolated from 
Phyllospongia papyracea. 
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The structure of the active compound was determined to be Phenol, 3,5-dibromo-2-(3,5-
dibromo-2-methoxyphenoxy). 
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  Characterization of compound 3 isolated from Monanchora unguiculata – Semi-
preparative HPLC was used to separate chromatographic peaks. One sample collected was found 
to exhibit antimicrobial activity. The sample appeared as a light yellow glue. Although this 
appeared as a single chromatographic peak, and was believed to be a pure compound, compound 3 
actually contains a mixture of compounds.  Through comparison of 
1
H and 
13
C NMR data
 
with 
those reported in the literature regarding similar marine species, it was found that the sample 
exhibited the same ‘vessel’ part system and relative stereochemistry as crambescidin 800, 
ptilomycalin A, and fromianmycalin [67-70]. Further analysis of
 1
H, 
13
C NMR data established 
that a spermidine residue was present, as the ‘anchor’ however, the exact structure could not be 
differentiated. By analysis of DEPT, COSY, TOCSY, HSQC, and HMBC, one of spermidine 
residues was the same as fromianmycalin [69]; one of as crambescidin 800 [67]; another as 
ptilomycalin A [67, 68], however, the hydroxyl group could not be assigned.  
The compound mixture appeared as a light yellow oil, [α]
20
 D 0° (c 0.21, MeOH); UV 
(MeOH/water) λmax 248nm; HRESIMS m/z 801.6217 [M+H]
+
 401.8152 [M+2]/2 (calcd for C45H81 
N6O6,  801.6218, monanchocidin F and crambescidin 800); 392.8095 [M+2]/2 (calcd for C45H79 
N6O5,  783.6112, fromianmycalin) ;  EIMS m/z 782.9 (1.2), 709.8 (2.2), 683.8 (4.3), 643 (3.3), 
613.7 (2.8), 574.7 (6.6), 544.6 (4.8), 503.3 (8.2), 429.3 (14.9), 402.4 (11.3), 360.4 (12.8), 359.4 
(23.5), 358.4 (23.7), 330.4 (27.3), 312.4 (24.7), 311.5 (24.2), 288.3 (23.9), 262.3 (31.1), 261.3 
(26.6), 192.2 (33.1), 191.2 (33.7), 149.2 (29.6),113.2 (25.1), 111.2 (25.8), 98.2 (31.1), 99.2 (28.2), 
36.0 (100). 
In HRESIMS spectrum, a pseudomolecular ion, [M+H], at m/z 801.6217, and two 
[M+2]/2 ion peak groups at m/z 401.3131, 401.8152, 402.3191, and 402.8218; 392.3080, 
392.8095, 393.3137, and 393.8580, were assigned the molecular formula C45H80N6O6 and 
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C45H79N6O5, respectively. EIMS data presented the fragmentation ion at m/z 729 (M-71) and 613 
(M-187) from M ion (m/z 800), corresponding to the losses of C4H9N and C9H21N3O, 
respectively, which showed the existence of ptilomycalin A’s spermidine residue again. The 
position of hydroxyl group was assigned at C-33 depending on the one pair of ion at m/z 574/326 
and 544/356 (scheme 5). The configuration of C-33 can not be determined based on the results of 
the application of the Mosher’s method because Δδ of C-32 and 34 showed the same positive 
value. And the optical value was 0°. This was identified as one new compound, a polycyclic 
guanidine alkaloid, monanchocidin F (Figure 7), the NMR data were assigned as Table 3 
dependent on 2D NMR as well as two known compounds crambescidin 800 and fromianmycalin 
(Figure 8). 
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Tabel 4. 
1
H and 
13
C NMR data for compound mixture in compound 3 (in CD3OD,) 
 
 Monanchocidin F Crambescidin 800 Fromianmycalin 
 
1
H NMR
 1
H NMR
 1
H NMR
 13
C NMR 
1
H NMR
 13
C NMR 
1 0.86, t, 7.8Hz 0.86, t, 7.8Hz 0.86, t, 7.8Hz 9.42 0.86, t, 7.8Hz 9.42 
2a 1.45, m 1.45, m 1.45, m 26.17 1.45, m 26.17 
2b 1.51, m 1.51, m 1.51, m  1.51, m  
3 4.40, br d, 12.0 Hz 4.40, br d, 12.0 Hz 4.40, br d, 12.0 Hz 72.3 4.40, br d, 12.0 Hz 72.3 
4 5.49, br d, 12.0 Hz 5.49, br d, 12.0 Hz 5.49, br d, 12.0 Hz 132.93 5.49, br d, 12.0 Hz 132.93 
5 5.68, br t, 12.0 Hz 5.68, br t, 12.0 Hz 5.68, br t, 12.0 Hz 129.88 5.68, br t, 12.0 Hz 129.88 
6a 2.13, m 2.13, m 2.13, m 23.01 2.13, m 23.01 
6b 2.35, m 2.35, m 2.35, m  2.35, m  
7a 1.94, m 1.94, m 1.94, m 38.17 1.94, m 38.17 
7b 2.38, m 2.38, m 2.38, m  2.38, m  
8    83.64  83.64 
9a 1.40, t, 12.0 Hz 1.40, t, 12.0 Hz 1.40, t, 12.0 Hz 37.86 1.40, t, 12.0 Hz 37.86 
9b 
2.62, dd, 15.6, 6.0 Hz 2.62, dd, 15.6, 6.0 
Hz 
2.62, dd, 15.6, 6.0 
Hz 
 2.62, dd, 15.6, 6.0 
Hz 
 
10 4.04, m 4.04, m 4.04, m 54.10 4.04, m 54.10 
11a 1.68, m 1.68, m 1.68, m 30.12 1.68, m 30.12 
11b 2.24, m 2.24, m 2.24, m  2.24, m  
12a 1.65, m 1.65, m 1.65, m 28.19 1.65, m 28.19 
12b 2.26, m 2.26, m 2.26, m  2.26, m  
13 4.33, m 4.33, m 4.33, m 52.55 4.33, m 52.55 
14 3.06, d, 6.0 3.06, d, 6.0 3.06, d, 6.0 49.34 3.06, d, 6.0 49.34 
15    80.68  80.68 
16a 1.52, m 1.52, m 1.52, m 32.73 1.52, m 32.73 
16b 1.80, m 1.80, m 1.80, m  1.80, m  
17a 1.79, m 1.79, m 1.79, m 18.04 1.79, m 18.04 
17b 1.91, m 1.91, m 1.91, m  1.91, m  
18a 1.75, m 1.75, m 1.75, m 32.55 1.75, m 32.55 
18b 1.92, m 1.92, m 1.92, m  1.92, m  
19 
3.84, br dd, 12.6, 6.0 
Hz 
3.84, br dd, 12.6, 6.0 
Hz 
3.84, br dd, 12.6, 6.0 
Hz 
68.40 3.84, br dd, 12.6, 6.0 
Hz 
68.40 
20 1.07, d, 7.2 Hz 1.07, d, 7.2 Hz 1.07, d, 7.2 Hz 20.40 1.07, d, 7.2 Hz 20.40 
21    150.1  150.1 
22    168.71  168.71 
23 4.11, t, 7.2 Hz 4.11, t, 7.2 Hz 4.13, t, 7.2 Hz 68.55 4.11, t, 7.2 Hz 68.55 
24 1.63, m 1.63, m 1.97 39.93 1.63, m 39.93 
25 1.29, m 1.29, m 4.03 67.04 1.29, m 67.04 
26 1.29, m 1.29, m 1.41 37.86 1.29, m 37.86 
27 1.29, m 1.29, m 1.29, m 28.84-30.12 1.29, m 28.84-30.12 
28-31 1.29, m 1.29, m 1.29, m 28.84-30.12 1.29, m 28.84-30.12 
32 1.69 1.29, m 1.29, m 28.84-30.12 1.29, m 28.84-30.12 
33 4.03, m 1.29, m 1.29, m 28.84-30.12 1.29, m 28.84-30.12 
34 1.40 1.29, m 1.29, m 28.84-30.12 1.29, m 28.84-30.12 
35 1.29 1.29, m 1.29, m 28.84-30.12 1.29, m 28.84-30.12 
36 1.80, m 1.80, m 1.80, m 27.67 1.80, m 27.67 
37 2.48, m 2.48, m 2.48, m 32.76 2.48, m 32.76 
38    166.36  166.36 
41 
 
 
39a 3.37, m 3.38, m 3.38, m 47.84 3.38, m 47.84 
39b 3.62, m 3.64, m 3.56, m  3.64, m  
40 1.92, m 1.92, m 2.07, m 19.86 1.92, m 19.86 
41 2.88, m 2.88, m 3.38, m 39.94 2.88, m 39.94 
   3.53, m    
42a 3.51, m 3.32 3.41, m 58.51 3.32 58.51 
42b 3.63, m 3.46 3.69, m  3.46  
43a 1.95 m 3.95, m 4.03, m 69.38 3.95, m 69.38 
43b 2.05 m      
44 1.65, m 1.75 1.75 32.87 1.75 32.87 
 1.75, m 1.93 1.93  1.93  
45 3.12, m 3.12, m 3.12, m 38.52 3.12, m 38.52 
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Figure 7 Chemical structure of a component of compound 3; monanchocidin F isolated from 
Monanchora unguiculata 
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The mixture of compounds was determined to include the new compound monanchocidin F, 
where R1=OH, R2=H. 
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Figure 8 Chemical structure of components of compound 3; the compounds cambescidin and 
fromianmycalin, isolated from Monanchora unguiculata. 
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The mixture of compounds was determined to include the known compounds crambescidin 800, 
where R1=H, and fromainmycalin, where R2= OH.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
44 
 
 
Scheme 5 Characterization of new compound monanchocidin F by MS fragmentation (m/z 
values).  
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  Characterization of compound 4 isolated from Dysidea herbacea – Fractionation of 
Dysidea herbacea extract led to the isolation of a single known compound. The compound 
appeared as a light yellow glu. 
1
H NMR (methanol-d4, 500 MHz) δ 7.32 (1H, d, J=2.5 Hz, H-4′), 
6.43 (1H, d, J=2.5 Hz, H-6′); 13C NMR (methanol-d4, 125.7 MHz) δ 150.3 (C-1), 146.6 (C-1′), 
145.1 (C-2′), 141.1 (C-2), 130.1 (C-4′), 126.7 (C-3), 121.3 (C-4), 118.9 (C-5), 116.8 (C-6), 116.3 
(C-6′), 112.2 (C-3′), 111.2 (C-5′); ESIMS [M-H]- m/z 668.91 (2), 670.86 (24), 672.89 (74), 
674.87 (100), 676.85 (67), 678.88 (22), 680.8 7(2); ESIMS [M+Na]
+
 m/z 691.92 (3), 694.89 
(24), 696.85 (65), 698.85 (100), 700.85 (58), 702.83 (19), 705.13 (3). Through comparison of 
spectral data previously reported in the literature, the compound was determined to be the 
tetrabrominated diphenyl ether: 2-(3′,5′-dibromo-2′-hydroxyphenoxy)-3,4,5,6-tetrabromophenol 
[71-73] (Table 5). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
 
 
Table 5 
1
H and 
13
C NMR spectral data of compound 2 isolated from Dysidea herbacea. 
 
Position 
1
H 
13
C 
1  150.3 
2  141.1 
3  126.7 
4  121.3 
5  118.9 
6  116.8 
1′  146.6 
2′  145.1 
3′  112.2 
4′ 7.32 (1H, d, J=2.5) 130.1 
5′  111.2 
6′ 6.43 (1H, d, J=2.5 ) 116.3 
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Figure 9 Chemical structure of compound 4; an oxy-polyhalogenated diphenyl ether isolated 
from Dysidea herbacea. 
 
O
OH OH
Br
Br
Br
Br
Br
Br
 
The structure of the active compound was determined to be 2-(3′,5′-Dibromo-2′-
hydroxyphenoxy)-3,4,5,6-tetrabromophenol. 
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Discussion 
 
The activity-driven isolation of the M. africana extract led to the identification of an 
active component, mammea A/AA.  Mammea A/AA is a 4-phenylcoumarin that has shown in 
vitro anti-proliferative  activity on a variety of cancer cells [39, 45, 74, 75], high antioxidant 
activity [45], and low cytotoxicity to normal cells [75-77], suggesting that mammea A/AA 
possesses unique bioactivities worth further investigation. The compound has also been found to 
inhibit the growth of methicillin resistant Staphylococcus aureus (MRSA), and methicillin 
susceptible Staphylococcus aureus (MSSA), as well as Enterococcus faecalis bacteria [39, 42, 
43]. The compound mammea A/AA was also previously tested for in vitro susceptibility against 
strains of Escherichia coli, Enterobacter cloacae, Serratia marcescens, Pseudomonas 
aeruginosa, Acinetobacter spp., as well as Candida albicans and Cryptococcus neoformans. 
Mammea A/AB combined with mammea A/AA in the ratio 4:1 was proven to be ineffective as 
an antimicrobial against these gram-negative bacteria and fungi demonstrating MICs above 128 
µg/ml [42]. 
Mammea A/AA has previously been studied by a number of research groups in an effort 
to evaluate its anti-cancer activity. This compound was found to exhibit cytotoxicity against the 
human 9-KB cancer cell [39]. Researchers also found mammea A/AA to exhibit cytotoxic 
activities in the SW-480, HT-29, and HCT-116 human colon cancer cell lines at concentrations 
comparable to 5-fluorouracil, a drug frequently used for human colon cancer treatment [45]. An 
IC50 value of 6.4 µg/ml for mammea A/AA cyclo has been reported for its cytotoxicity against 
A2780 ovarian cancer cells [74]. The cytotoxicity of mammea A/AA was assayed using four 
cancer cell lines (HeLa, Calo, SW480, and SW620) and the normal peripheral-blood 
mononuclear cells. Results proved that mammea A/AA induced an apoptosis-like cell death in all 
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tested cancer cell lines, while showing very low cytotoxicity levels in normal peripheral-blood 
mononuclear cells [75]. Furthermore, an investigation of the cytotoxicity of mammea A/AA on 
normal human lymphocyte cultures, found that mammea A/AA did not show toxicity, and 
demonstrated an LC100 of 120.5 µg/ml [76].  Similarly, this compound was found to be non-toxic 
at 50 µM [77]. Support for the further development of mammea A/AA and other mammea 
coumarins is prevalent among researchers studying this class of compounds, which are thought 
to have significant potential as an alternative antimicrobial in the prevention and treatment of 
human infections, and applications as a promising candidate for anticancer treatment.  
Bioactivity-guided isolation of the P. papyracea extract led to the identification of the 
active component, 4,6-Dibromo-2-(4,6-dibromo-2-hydroxyphenol) anisole [53]. This compound 
was previously tested for its antimicrobial activity and was found to possess antimicrobial 
activity by inhibiting S. aureus and T. mentographytes (MIC100 0.15, 1.56 µg/ml, respectively) 
[50]. Furthermore, it has been found to posess antimicroalgal activity against S. costatum and B. 
submaria at 0.5 p.p.m. [53]. A compound with a structure later revised to match this compound 
was found to inhibit hypoxia-induced HIF-1 activation (IC50=4.3µM), but also reduced the 
viability of T47D and MDA-MD-231 breast tumor cells [4].  
The fractionation of a M. unguiculata extract led to isolation of a group of polycyclic 
guanidine alkaloids. Similar compounds have previously been isolated from the marine sponge 
Monanchora pulcha. The known compounds which were idenitfied as being present were 
crambescidin 800, fromainmycalin, and ptilomycalin A. An unknown compound was identified 
as Monanchocidin F. The first identified monanchocidin compound, monachocidin A was 
revealed as exhibiting a number of uncommon features [57]. Recently, the monanchocidins B-E 
were revealed which contain the same structural features; the polycyclic moiety previously 
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referred to as the “vessel”, the vicinal hemiketal in a substituted morpholinone ring “anchor” and 
hydrocarbon “chain”[78]. The monanchocidin group has previously identified as exhibiting 
cytotoxicity against a number of human cell lines, including human leukemia THP-1 (IC50 5.1 
µM), and human cervix epitheliod carcinoma Hela (IC50 11.8 µM). This compound was also 
found to inhibit mouse epidermal JB6 C141 (IC50 12.3 µM) cell lines [57].  
Bioactivity-driven isolation of the antimicrobial component of the final extract, D. 
herbacea led to the compound 2-(3′,5′-Dibromo-2′-hydroxyphenoxy)-3,4,5,6-tetrabromophenol. 
The oxy-polyhalogenated diphenyl ether group of compounds has previously been found to 
display inhibitory activity against the bacteria Bacillus subtilis and fungus Cladosporium 
cucumerinum [61]. Their range of activities also includes anti-inflammatory properties, 
lipoxygenase inhibition, and anticancer activity [79, 80].  The oxy-polyhalogenated diphenyl 
ether group has been investigated for the compounds’ ability to inhibit the overexpression of 
Mcl-1 in cancerous cells and it was concluded that these compounds may take advantage of a 
synergistic or additive effect, where combined compounds exhibit activities greater than a single 
isolated oxy-halogenated diphenyl ether [73].  
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CHAPTER 3: CHARACTERIZATION OF ANTIMOCROBIAL ACTIVITY OF 
ISOLATED COMPOUNDS  
Minimum Inhibitory Concentration (MIC) 
Introduction  
Broth microdilution is the most popular method for performing antimicrobial 
susceptibility testing in the U.S. One of the reasons for its popularity is that it produces results 
comparable to the “gold standard”: the agar dilution method. Furthermore this method is useful 
when testing a number of isolates at a number of different concentrations [81]. The protocol for 
this method is available in the Clinical and Laboratory Institutes (CLSI) document M7-A8 and 
M11-A8 [37, 38].  The lowest concentration of an antibiotic that will inhibit the growth of the 
organism being tested is referred to as the minimal inhibitory concentration (MIC). This value is 
usually expressed in µg/ml and is useful to clinicians to determine the appropriate antibacterial 
agent and dosage to be used to treat a patient [82].  Antibiotic agents are included in assays for a 
variety of reasons. An antibiotic known to inhibit the bacterial species being tested must be 
included as a quality control. An antibiotic agent that is currently used to treat the bacterial 
infection must also be included in the assays in order for researchers to compare the efficacy of 
the natural antimicrobial with that of pharmaceutical agents. Finally, antibiotics may be included 
in the tests to determine susceptibility of a bacterial species to the antibiotic. 
Materials and Methods 
The bacterial species included in MIC determination testing were: A. baumanii, Bacillus 
subtilis; ATCC 6051, C. jejuni, Escherichia coli 0157 H:7; ATCC 25922, Listeria 
monocytogenes; ATCC 23074, K. pneumoniae, P. aeruginosa, Salmonella enterica serovar 
thyphimurium; ATCC 19585, Staphylococcus areus; NCTC 8325 and S. pneumoniae. The 
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original plant extract and the active compound were dissolved in dimethyl sulfoxide (DMSO) to 
produce a stock solution with the concentration of 1 mg/ml. This was further diluted in sterile 
distilled water to prepare test solutions with the concentration of 100 µg/ml. MIC evaluations of 
aerobic and anaerobic bacteria were determined by the broth microdilution method according to 
CLSI guidelines [37, 38]. MIC evaluations of microaerophilic bacteria were determined as 
previously described [83]. In brief, bacterial colonies were selected from 24 h cultures, 
suspended in sterile distilled water and adjusted to match a 0.5 McFarland standard by measuring 
absorbance at 625 nm using an HTS 7000 Bio Assay Reader (Perkin Elmer, Norwalk, CT). The 
bacterial cell numbers were adjusted to approximately 1 x 10
5 
colony forming units (CFU)/ml in 
CAMHB, BHI broth, or nutrient broth. Plant extracts, isolated active compounds, and antibiotics 
(100 µg/ml) were subjected to serial two-fold dilution in a 96-well microtiter plate. Final test 
concentrations ranged from .0125 to 16 µg/ml. Assay plates were incubated in appropriate 
conditions (aerobic, anaerobic, or microaerophilic) at 37 ºC for 24 h, and growth was assessed by 
measuring absorbance at 625 nm using the Bio Assay Reader. MIC’s of antibiotic agents was 
interpreted as the lowest concentration of antibiotic agent to cause an 80% or greater reduction of 
growth compared to the growth control. The growth control consisted of DMSO diluted in sterile 
distilled water (1:9), and broth, but no test samples. A blank containing no bacteria was also 
included. Stock solution of antibiotics, erythromycin, carbenicillin, ciprofloxacin, cefoxitin, 
fusidic acid, imipenem, levofloxacin, moxifloxacin, rifampicin, tetracycline, and vancomycin 
were prepared according to manufacturer’s suggestions. These were diluted to 100 µg/ml in 
sterile distilled water and included in the assay. The assays were performed three times and MIC 
values were reported as the mean value of each assay. 
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Results  
Compound 1 isolated from M. africana displayed inhibitory activity on A. baumannii at 2 
µg/ml, while the original M. africana extract did not exhibit inhibitory activity on this bacterial 
species even at 16 µg/ml. Furthermore, compound 1 inhibited the growth of the bacteria B. 
subtilis, C. jejuni, L. monocytogenes, P. aeruginosa, S. aureus, and S. Pneumoniae with MIC 0.5 
µg/ml. Compound 1 did not inhibit E. coli O157:H7, K. Pneumoniae, or S. Typhimurium at 
concentrations up to 16 µg/ml as displayed in Table 6.  
Compound 2 isolated from P. Papyracea displayed inhibitory activity against B. subtilis 
at a concentration of 1 µg/ml, C. jejuni at 2 µg/ml, L. monocytogenes at 8 µg/ml, P. aeruginosa 
at 4 µg/ml, S. aureus at 1 µg/ml, and S. pneumoniae at 1 µg/ml (Table 7). Compared with the 
original extract, the isolated compound displayed a reduced bioactivity, with the isolated 
compound displaying MIC’s at levels between 1 and 4-fold higher than the original extract. 
Compound 2 did not show inhibition of growth for the bacteria A. baumannii, E. coli 0157:H7, 
K. pneumoniae, or S. typhimurium at concentrations up to 16 µg/ml.   
The mixture of compounds in the fraction known as compound 3 displayed antimicrobial 
activity against S. aureus at 0.25 µg/ml, B. subtilis at 0.5 µg/ml, C. Jejuni, L. monocytogenes, P. 
aeruginosa, and S. pneumoniae at 2 µg/ml, and E. coli 0157:H7, K. pneumoniae, and S. 
typhimurium at 4 µg/ml (Table 8). This mixture of compounds was found to be an excellent 
inhibitor of every species of bacteria included in the experiment. The mixture of compounds 
displayed activity comparable to the original extract. MIC’s for the mixture of compounds was 
equal to or within 2-fold higher or lower than the MIC of the original extract. Furthermore, 
compound 3 was the only one of the 4 compounds which inhibited the bacterial species, E. coli 
0157:H7, K. pneumoniae, and S. typhimurium.  
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Compound 4, isolated from D. herbacea, displayed inhibitory activity on B. subtilis and 
S. pneumoniae at 0.5 µg/ml, C. Jejuni  and P. aeuruginosa at 0.25 µg/ml, L. monocytogenes at 2 
µg/ml, and S. aureus at 0.125 µg/ml (Table 9). The isolated compound displayed MIC’s at or 
below the MIC of the original extract. This compound failed to inhibit the bacterial species A. 
baumannii, E. coli, K. pneumoniae, and S. typhimurium at concentrations up to 16 µg/ml.  
  MIC’s of commonly used antibiotics against the tested bacterial strains were also 
included for comparison. Imipinem, a pharmaceutical agent displayed an MIC at 0.125 µg/ml 
against A. Baumannii (Table 10). B. subtilis was inhibited by the antibiotic agents ciprofloxacin, 
carbenicillin and tetracycline at 0.25 µg/ml, 0.125 µg/ml and 0.5 µg/ml, respectively. C. jejuni 
was inhibited by moxifloxacin at 0.125 µg/ml, ciprofloxacin and levofloxacin at 0.25 µg/ml and 
erythromycin at 0.5 µg/ml. E. coli was inhibited by the antibiotics moxifloxacin at 0.125 µg/ml, 
and ciprofloxacin and levofloxacin at 0.25 µg/ml. However, erythromycin and vancomycin did 
not inhibit E.coli bacteria at concentrations up to 16 µ/ml. L. Monocytogenes was inhibited by 
erythromycin at 0.25 µg/ml, tetracycline and vancomycin at 0.5 µg/ml and carbenicillin at 8 
µg/ml. K. pneumoniae was inhibited by ciprofloxacin at 0.125 µg/ml and at 0.25 µg/ml by 
cefoxitin and imipenem. P. aeruginosa was inhibited by carbenicillin at 0.25 µg/ml and 
ciprofloxacin and imipenem at 0.125 µg/ml. MIC of the antibiotics ciprofloxacin and imipenem 
on S. typhimurium were 0.125 and 1 µg/ml, respectively. S. pneumoniae was inhibited by 
ciprofloxacin, levofloxacin, and moxifloxacin at 0.125 µg/ml. Finally, S. aureus was inhibited by 
the antibiotic agents fusidic acid and rifampicin at 0.125 µg/ml and carbenicillin and 
erythromycin at 0.5 µg.ml.  
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Table 6 The minimum inhibitory concentration (µg/ml) of bacterial growth of bacterial strains 
exerted by Mammea africana plant crude extract and the isolated coumarin mammea A/AA; 
compound 1. 
 
 
* Each value represents the mean of three observations.  
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Table 7 The minimum inhibitory concentration (µg/ml) of bacterial growth of bacterial strains 
exerted by Phyllospongia papyracea plant crude extract and the isolated tetrabrominated 
diphenyl ether; compound 2. 
 
 
* Each value represents the mean of three observations. 
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Table 8 The minimum inhibitory concentration (µg/ml) of bacterial growth of bacterial strains 
exerted by Monanchora unguiculata plant crude extract and the isolated active mixture of  
compounds; compound 3. 
 
 
* Each value represents the mean of three observations. 
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Table 9 The minimum inhibitory concentration (µg/ml) of bacterial growth of bacterial strains 
exerted by Dysidea herbacea plant crude extract and the isolated active compound; compound 4. 
 
 
* Each value represents the mean of three observations. 
 
  
 
* Each value represents the mean of three observations. 
   
 
Table 10 The minimum inhibitory concentration (µg/ml) on bacterial growth of bacterial strains exerted by commonly used antibiotics.  
Antibiotic MIC (µg/ml)* 
  Erythromycin Carbenicillin Ciprofloxacin Cefoxitin Fusidic 
Acid 
Imipenem Levofloxacin Moxifloxacin Rifampicin Tetracycline Vancomycin Metronidazole 
 Acinetobacter 
Baumannii 
 
- 
 
 
- 
 
- 
 
- 
 
- 
 
0.125 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 Bacillus Subtilis  
- 
 
 
0.25 
 
0.125 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
0.5 
 
- 
 
- 
 Campylobacter 
Jejuni 
 
0.5 
 
- 
 
0.25 
 
- 
 
- 
 
- 
 
0.25 
 
0.125 
 
- 
 
- 
 
- 
 
- 
5
9
 Escherichia coli 
0157 H:7 
 
>16 
 
- 
 
0.125 
 
- 
 
- 
 
- 
 
- 
 
- 
 
4 
 
1 
 
>16 
 
- 
 Listeria 
Monocytogenes 
 
0.25 
 
8 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
0.5 
 
0.5 
 
- 
 Klebsiella 
Pneumoniae 
 
 
- 
 
- 
 
0.125 
 
0.25 
 
- 
 
0.25 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 Pseudomonas 
Aeruginosa 
 
 
- 
 
0.25 
 
0.125 
  
- 
 
0.125 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 Salmonella 
Typhimurium 
 
 
- 
 
- 
 
0.125 
  
- 
 
1 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 Streptococcus 
Pneumoniae 
 
- 
 
- 
 
0.125 
  
- 
 
- 
 
0.125 
 
0.125 
 
- 
 
- 
 
- 
 
- 
 Staphylococcus 
Aureus 
 
0.5 
 
0.5 
 
- 
  
0.125 
 
- 
 
- 
 
- 
 
0.125 
 
- 
 
- 
 
- 
  
 
Discussion 
 
The inclusion of commonly used antibiotics served three purposes. The first is as a 
quality control measure, by aiding in the determination that strains are susceptible to antibiotics 
that they should be. Second of all, we were able to determine if the specific strains being tested 
were resistant to commonly-used antimicrobials. Third, they were useful for comparison of the 
activity of our compounds.   
The A. baumannii strain used was susceptible to the antibiotic imipenem based on the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints 
[84]. A. baumannii has been proven to be multi-drug resistant and to have unpredictable 
susceptibility patterns [85]. Therefore, replacements to conventional therapies are always 
needed. Compounds 1 and 3 show a high level of inhibitory activity on this bacterial species and 
could be considered for further study. 
  B. subtilis was considered susceptible to the antibiotic ciprofloxacin based on EUCAST 
breakpoints. All four compounds inhibited this species of bacteria with an MIC of 1 µg/ml or 
lower, and compounds 1, 3, and 4 all inhibited at a level equivalent to the commonly-used 
antibiotic tetracycline (MIC = 0.5 µg/ml) 
  Based on clinical breakpoints, the C. jejuni species used was susceptible to the 
antibiotics erythromycin and ciprofloxacin. While all four compounds displayed inhibitory 
activity of equal to or less than 2 µg/ml, compound 4 was the most effective, inhibiting at 0.25 
µg/ml, equivalent to the commonly used antibiotics ciprofloxacin and levofloxacin.  
  The strain of E. coli 0157H7 tested was susceptible to the commonly-used antibiotic 
ciprofloxacin, but was not inhibited by erythromycin or vancomycin even at 16 µg/ml. Of the 
four compounds tested, only compound 3 was able to inhibit the growth of the bacteria. 
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Compound 3 inhibited the strain of E. coli at 4 µg/ml, but it is also important to note that the 
original M. unguiculata extract displayed equivalent activity. Both the compound mixture and 
the extract displayed activity at the level of the antibiotic rifampicin.  
  The L. monocytogenes strain tested displayed susceptibility to the antibiotic 
erythromycin based on EUCAST breakpoints. Compound 1 was found to have the strongest 
inhibitory activity of the isolated compounds at MIC of 0.5 µg/ml. This is equivalent to two 
commonly used antibiotics, tetracycline and vancomycin. Compounds 3 and 4 displayed 
inhibitory activity at 2 µg/ml, proving they too have potential applicability as replacement 
antimicrobials for this common pathogen.  
  K. pneumoniae was susceptible to the commonly used antibiotics ciprofloxacin and 
imipenem in this test. Compound 3 was the only isolated product to inhibit this species of 
bacteria. The MIC of 4 µg/ml was equivalent to the MIC of the M. unguiculata extract, which 
leads to the belief that other active compounds exist within the extract and together create an 
additive effect.  
  P. aeruginosa was susceptible to the commonly used antibiotics ciprofloxacin and 
imipenem. Compound 4 showed the most prominent activity against P. aeruginosa, with an MIC 
of 0.25 µg/ml; equivalent to the antibiotic carbenicillin. The MIC of compound 1 was 0.5 µg/ml, 
proving either compound could be a potential alternative for current pharmaceuticals.  
  S. typhimurium was susceptible to the two antibiotics commonly used for its treatment; 
ciprofloxacin and imipenem. Only compound 3 displayed inhibitory activity on this species of 
bacteria (MIC = 4 µg/ml). Furthermore, the MIC of the isolated mixture of compounds was 
higher than the MIC for the M. unguiculata extract.  
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  S. pneumoniae was susceptible to ciprofloxacin, levofloxacin, and moxifloacin. 
Compounds 1 and 4 displayed a high level of activity with MICs of 0.5 µg/ml.  
  S. aureus was proven to be susceptible to antibiotics erythromycin, fusidic acid, and 
rifampicing based on EUCAST breakpoints. All of the isolated products tested inhibited this 
strain of bacteria at or below 1 µg/ml. Compound 4 displayed the greated activity, with an MIC 
of only 0.125 µg/ml, which is equivalent to or greater than all the antibiotics included.  
In conclusion, the four compounds isolated displayed broad-spectrum antimicrobial 
activity.  All of the compounds were successful at inhibited both gram-positive and gram-
negative bacteria. The gram-negative bacteria posed a greater challenge to the compounds, as 
compounds 1, 2, and 4 failed to inhibit the same three gram negative bacteria; E. coli 0157: H7, 
K. pneumoniae, and S. typhimurium. These three bacterial species are all part of the same family, 
known as enterobaceriaceae. Furthermore, compounds 2 and 4 also failed to inhibit gram 
negative A. baumannii at concentrations up to 16 µg/ml. The isolated mixture of compound 3 
successfully inhibited the gram-positive bacteria as well as these more challenging gram negative 
bacteria, proving superior antimicrobial ability. Unfortunately, for the most part, fractionation of 
M. unguiculata did not lead to improved activity over the original extract. Further testing would 
likely lead to other active compounds in the M. unguiculata extract. Combining a number of 
isolated compounds would likely produce a stronger effect than the original extract, however, the 
low MIC values obtained prove that M. unguiculata extract may have potential antimicrobial use 
even without fractionation.  
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Minimum Bactericidal Concentration (MBC) 
Introduction 
The MIC test proves the inhibitory activity of the sample tested; however, it does not 
indicate the action of the antibacterial agent. Researchers often improve the MIC testing by 
testing to see if growth of the microorganism will begin again following the removal of the 
antibacterial agent. Therefore, it is important to follow-up this test by determining the minimal 
bactericidal concentration (MBC) of the sample. MBC is the lowest concentration of an 
antibiotic to kill 99.9% of a bacterial inoculum [82]. Researchers use these two tests to determine 
the mode of action of the antimicrobial compound, being either bacteriostatic or bactericidal.       
Materials and Methods 
  Following the broth microdilution test for MIC, 20 µl of suspension was removed from 
each microtitre plate well showing no growth, and transferred to a new well containing 240 µl of 
sterilized broth. Following a 24 hour incubation period at 37 ºC in appropriate conditions, the 
results were obtained by measuring absorbance at 625 nm. The MBC was determined as the 
lowest concentration of antibacterial agent in the original MIC test sample to cause a one-
thousand fold reduction in bacterial growth compared with the growth control (99.9% killing).   
Results 
 
  The effect of compound 1 on the bacterial species A. baumannii is considered 
bactericidal as the MIC and MBC are equal. For the remaining bacterial species inhibited by 
compound 1, a 1 to four-fold increase in concentration was required to obtain a bactericidal 
effect; with the exception of B. subtilis with an MBC 32-fold greater than the recorded MIC 
(Table 11).  
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  Similarly, a bactericidal effect was seen at the MIC of compound 2 on the bacterial 
species C. jejuni and L. monocytogenes. By increasing the concentration by 1 to 4fold more than 
the MIC value, a bactericidal effect could be produced for the other bacterial species (Table 12). 
Against B. subtilis, the bacteriocidal effect was not evident even up to concentrations of 16 
µg/ml. In most cases, the original P. papyracea extract exhibited stronger bactericidal effect than 
the isolated compound 2.   
  The mixture of compounds present in compound 3 displayed strong bactericidal activity 
with MBCs equal to the MICs for A. baumannii, C. jejuni, E. coli 0157:H7, K. pneumoniae, P. 
aeruginosa, and S. pneumoniae (Table 13). MBCs were slightly increased from the MICs for L. 
monocytogenes, S. typhimurium, and S. aureus. Finally, 16 µg/ml of the compound mixture was 
required to obtain a bactericidal effect on the bacterial species B. subtilis, although the MIC was 
0.5 µg/ml. 
Finally, compound 4 exerted bactericidal activity on S. pneumoniae at the MIC of 0.5 
µg/ml. A bactericidal effect could be seen at 2-8x the MIC for all other bacterial species involved 
(Table 14).  
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Table 11 The minimum bactericidal concentration (MBC) of bacterial growth of bacterial 
strains exerted by Mammea africana plant crude extract and the isolated coumarin mammea 
A/AA; compound 1. 
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Table 12 The minimum bactericidal concentration (MBC) of bacterial growth of bacterial 
strains exerted by Phyllospongia papyracea plant crude extract and the isolated tetrabrominated 
diphenyl ether; compound 2. 
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Table 13 The minimum bactericidal concentration (MBC) of bacterial growth of bacterial 
strains exerted by Monanchora unguiculata plant crude extract and the isolated active mixture 
of compounds; compound 3. 
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Table 14 The minimum bactericidal concentration (MBC) of bacterial growth of bacterial 
strains exerted by Dysidea herbacea plant crude extract and the isolated active compound; 
compound 4. 
 
 
* Each value represents the mean of three observations. 
  
 
 
* Each value represents the mean of three observations.
 
 
                           Table 15 The minimum bactericidal concentration (MBC) on bacterial growth of bacterial strains exerted by commonly used antibiotics. 
 
Antibiotic MBC (µg/ml)* 
  Erythromycin Carbenicillin Cefoxitin Ciprofloxacin Imipenem Fusidic 
Acid 
Levofloxacin Moxifloxacin Rifampicin Tetracycline Vancomycin Metronidazole 
 Acinetobacter 
Baumannii 
 
- 
 
- 
 
- 
 
- 
 
0.25 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 Bacillus Subtilis  
- 
 
4 
 
- 
 
0.5 
 
- 
 
- 
 
- 
 
- 
 
- 
 
4 
 
- 
 
- 
 Campylobacter 
Jejuni 
 
0.5 
 
- 
 
- 
 
0.5 
 
- 
 
- 
 
0.25 
 
0.125 
 
- 
 
- 
 
- 
 
- 
 Escherichia coli 
0157 H:7 
 
 
>16 
 
- 
 
- 
 
0.125 
 
- 
 
- 
 
- 
 
- 
 
8 
 
8 
 
>16 
 
- 
6
9
 
Klebsiella 
Pneumoniae 
 
Listeria  
Monocytogenes 
 
- 
 
        0.5 
 
- 
 
16                
 
16 
 
- 
 
0.125 
 
- 
 
0.25 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
2 
 
- 
 
1 
 
- 
 
- 
  
Pseudomonas 
Aeruginosa 
 
 
 
- 
 
 
1 
 
 
- 
 
 
1 
 
 
0.25 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 
 
- 
 Salmonella 
Typhimurium 
 
 
- 
 
- 
 
- 
 
0.125 
 
4 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 Staphyloccus 
Aureus 
 
 
0.5 
 
2 
 
- 
 
- 
 
- 
 
0.5 
 
- 
 
- 
 
0.125 
 
- 
 
0.5 
 
- 
 Streptococcus 
Pneumoniae 
 
- 
 
- 
 
- 
 
0.125 
 
- 
 
- 
 
0.125 
 
0.125 
 
- 
 
- 
 
- 
 
- 
  
 
Discussion 
  In most cases, the MIC represents a bacteriostatic activity. By increasing the 
concentration above the MIC, a bactericidal activity can be produced. Although breakpoint 
values only exist for MIC values, this trend is also true of the commonly used antibiotic agents, 
of which most required an increased concentration for their activity to be considered bactericidal. 
  Compounds 1, 2, and 3 could only produce a bactericidal effect on B. subtilis bacteria at 
high concentrations (MBC 16 µg/ml or above). Compound 4 displayed a far superior bactericidal 
activity on this bacterial species, with a low MBC of 4 µg/ml, making a good candidate for 
further drug development.  
  The mixture of compounds present in compound 3 displayed significant bactericidal 
activity against all the bacterial species included except B. subtilis. It can be concluded that this 
mixture of compounds has strong broad-spectrum bactericidal activity, which deserves further 
investigation.    
  Similar to the results of MIC testing, MBC testing showed decreased MBC values when 
the isolated product was compared with the original extract, only in the cases of compounds 1 
and 4. Compounds 2 and 3 often showed a higher MBC value than the original extract which 
further solidifies the hypothesis that some bioactive compounds were lost during fractionation. A 
second possible explanation is that the isolated compounds themselves degrade over time, losing 
activity, while the original extract is significantly more stable, and does not lose activity during 
storage. 
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CHAPTER 4: APPLICABILITY OF ISOLATED COMPOUNDS 
Introduction 
 
Stability testing evaluates the effect of environmental factors on the efficacy of a drug 
substance [86]. Stability testing to ensure product quality, safety, and efficacy are required prior 
to the approval of any pharmaceutical product. At the developmental stage, stability studies 
provide information required to determine shelf-life, packaging, and storage conditions [86]. The 
influence of environmental factors on the activity of the product being developed must be 
determined as temperature, humidity, and light are known to have a detrimental effect on some 
active compounds. In packaged foods, growth and survival of common spoilage and pathogenic 
microorganisms such as L. monocytogenes, E. coli 0157:H7, S. enterica serovar typhimurium, S. 
aureus, and C. Jejuni, are affected by a variety of intrinsic factors, such as pH and oxygen 
presence, as well as extrinsic factors of storage conditions, including temperature, time, and 
relative humidity [34]. The temperature of cooking may affect the antimicrobial compounds of 
natural products in foodborne pathogens. Therefore, heat treatment is required to determine if the 
antimicrobial compound has potential use as a commercial antimicrobial which could be applied 
to food products [87]. Stress testing of compounds often requires treatment with high heat, which 
serves not only the purpose of addressing the compound’s ability to withstand temperature 
associated with food storage, processing, cooking, or sterilization, but also as a method of 
accelerated aging. In this way, a compound that can withstand heat treatment at a high 
temperature is considered more likely to remain stable over long periods of storage. 
 Foods have various pH levels, usually ranging from pH 3 for foods such as cheese and 
pasta up to pH 10 for foods such as spinach and broccoli. If an antimicrobial agent becomes 
ineffective at a specific pH level, this will limit its potential application as a food preservative. 
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The role of pH level is important to consider as it has an effect on the growth rate of microbes, as 
well as the interaction of antimicrobial agent and microbial growth; affecting the MIC of the 
agent. The optimal pH for bacterial growth is usually between ph 6-8, however, even foods with 
pH levels at the far ends of the spectrum are subject to spoilage and/or pathogenic bacteria. 
Antimicrobial agents also have a specific pH at which they display optimal activity. Food 
preservatives have known optimal pH levels which are usually reflects the active moiety of the 
molecule and determines the application that the specific agent may be used for.  
  Finally, the shelf-stability of a potential pharmaceutical agent must be considered 
during the development stage of any drug. The optimal conditions of storage must be determined 
to facilitate proper packaging and storage instructions, as well as to estimate the product’s shelf-
life. Most products will remain stable longer if stored at lower temperatures, however, it is most 
convenient to store pharmaceutical products at room temperature. Exposure of the product to 
light is also important to consider as light is known to cause compound degradation, which will 
significantly impact the activity of a natural antimicrobial. Intermediate length testing should 
cover a minimum of six months duration, however, it is considered unnecessary to continue 
testing if a significant change in efficacy is seen in the first three months [88]. In general, a loss 
of activity up to 85% can lead to failure in therapy, and is considered significant loss of activity 
[86]. 
Materials and Methods 
  Thermal Stress Testing - Isolated compounds (100 µg/ml in water) were heated to 37ºC, 
50ºC, 80ºC, 100ºC, and 121ºC for 15 minutes using a Fisher Scientific Isotemp hot plate. 
Samples were removed to ice for 10 minutes for immediate cooling. Following heat treatment, 
the level of bioactivity of the compounds was assessed via broth microdilution method as 
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previously described [89]. Bacterial colonies of B. subtilis were selected from 24 h cultures, 
suspended in sterile distilled water and adjusted to match a 0.5 McFarland standard by measuring 
absorbance at 625 nm using an HTS 7000 Bio Assay Reader (Perkin Elmer, Norwalk, CT). The 
bacterial cell numbers were adjusted to approximately 1 x 105 colony forming units (CFU)/ml. 
Isolated active compounds stored in the freezer and compounds which had undergone heat 
treatment were subjected to serial two-fold dilution in a 96-well microtiter plate with final test 
concentrations ranging from .0125 to 16 µg/ml. Assay plates were incubated at 37 ºC for 24 h, 
and growth was assessed by measuring absorbance at 625 nm using the Bio Assay Reader. 
MIC’s of antibiotic agents was interpreted as the lowest concentration of antibiotic agent to 
cause an 80% or greater reduction of growth compared to the growth control. The growth control 
consisted of DMSO diluted in sterile distilled water (1:9), and broth, but no test samples. A blank 
containing no bacteria was also included. The assays were performed three times and MIC 
values were reported as the mean value of each assay. 
  Effect of pH Treatment - Buffers were prepared at pH 3, 4, 5, 6, 8, 9, and 10. Stock 
solutions of active compounds (1 mg/ml in DMSO) were evaporated under the fume hood 
overnight. Buffers or sterile distilled water (pH 7) were added to dried samples to achieve 
samples with a final concentration of 100 µg/ml. Samples were mixed using a vortex mixer. The 
level of bioactivity of the compounds was assessed via broth microdilution method as previously 
described. Bacterial colonies of B. subtilis were selected from 24 h cultures, suspended in sterile 
distilled water and adjusted to match a 0.5 McFarland standard by measuring absorbance at 625 
nm using an HTS 7000 Bio Assay Reader (Perkin Elmer, Norwalk, CT). The bacterial cell 
numbers were adjusted to approximately 1 x 10
5 
colony forming units (CFU)/ml. Isolated active 
compounds treated with buffers at various pH levels were subjected to serial two-fold dilution in 
74 
 
 
a 96-well microtiter plate with final test concentrations ranging from .0125 to 16 µg/ml. Assay 
plates were incubated at 37 ºC for 24 h, and growth was assessed by measuring absorbance at 
625 nm using the Bio Assay Reader. MIC’s of antibiotic agents was interpreted as the lowest 
concentration of antibiotic agent to cause an 80% or greater reduction of growth compared to the 
growth control. A set of growth controls was included in this assay in order to serve as a control 
for variations in growth of B. subtilis bacteria based on the inclusion of the buffers in the 
concentration range of .0125 to 16 µg/ml in the growth medium [90]. A blank containing no 
bacteria was also included.  
  Storage Conditions - Samples of isolated active compounds 1-4 (100 µg/ml in sterile 
distilled water) were placed in various storage conditions. The conditions chosen for testing 
were: -20ºC (freezer), 4ºC (fridge), room temperature without light exposure, and room 
temperature with light exposure. Samples were removed from storage at one month intervals and 
bioactivity was assessed by broth microdilution as previously described. Bacterial colonies of B. 
subtilis were selected from 24 h cultures, suspended in sterile distilled water and adjusted to 
match a 0.5 McFarland standard by measuring absorbance at 625 nm using an HTS 7000 Bio 
Assay Reader (Perkin Elmer, Norwalk, CT). The bacterial cell numbers were adjusted to 
approximately 1 x 10
5 
colony forming units (CFU)/ml. Isolated active compounds treated with 
varying storage environments were subjected to serial two-fold dilution in a 96-well microtiter 
plate with final test concentrations ranging from .0125 to 16 µg/ml. Assay plates were incubated 
at 37 ºC for 24 h, and growth was assessed by measuring absorbance at 625 nm using the Bio 
Assay Reader. MIC’s of antibiotic agents was interpreted as the lowest concentration of 
antibiotic agent to cause an 80% or greater reduction of growth compared to the growth control. 
The growth control consisted of DMSO diluted in sterile distilled water (1:9), and broth, but no 
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test samples. A blank containing no bacteria was also included.  They were tested for a period of 
6 months.  
Results 
 
  Thermal Stress Testing - Compound 1 did not show any loss in activity following heat 
treatment at 50 ˚C. Heat treatment at 80 ˚C caused a slight loss in activity which became more 
pronounced with treatment above 100 ˚C. Although this compound proved to be susceptible to 
heat treatment, even following treatment at 121 ˚C for 15 minutes, the compound was still able to 
inhibit the B. subtilis bacteria at a low MIC of 2 µg/ml (Figure 10). 
Thermal stability testing proved that compound 2 was the most susceptible to heat 
treatment. It had significant loss of activity against B. subtilis even when heated only to body 
temperature 37 ˚C. Following heat treatment of 80 ˚C for 15 minutes, the compound did not 
inhibit the growth of B. subtilis bacteria even at the highest tested concentration of 16 µg/ml. 
The mixture of compounds present in compound 3 was determined to be highly heat-
stable. Following heat treatment at 121 ˚C, the antimicrobial activity was only slightly decreased, 
producing a low MIC of 1 µg/ml. 
Compound 4 maintained its activity following heat treatment of 100 ˚C (MIC = 0.5 
µg/ml). It showed decreased activity following heat treatment at 121 ˚C displaying an MIC 
which increased to 4 µg/ml. 
  Effect of pH Treatment - None of the pH buffers on their own significantly inhibited the 
growth of the B. Subtilis bacteria, although, as expected, the highest level of bacterial growth 
was recorded when buffers at pH of 6 and 7 were included. This proves that even small amounts 
of basic or alkaline buffer will decrease the growth rate of the B. subtilis bacteria. Compound 1 
did not show any inhibition on the B. Subtilis even up to a concentration of 16 µg/ml. Compound 
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2 showed inhibition at the MIC level of 1 µg/ml with pH buffer 10 only. With pH buffer 9, the 
bacteria was inhibited at 4 µg/ml. Compound 3 showed inhibition at 16 ppm when buffers at pH 
3, 5, and 7 were included. Finally, compound 4 showed inhibition at 1 µg/ml when buffers at ph 
9 and 10 were included and at 4 µg/ml with buffer at pH 8.  
  Storage Conditions - Compound 2 showed significant loss of activity following storage 
at -20 ˚C by 2 months time. By 6 months, compound 2 displayed an MIC of 16 µg/ml, compared 
to an MIC of 1 µg/ml at Day 1. Compound 1 retained its bioactivity throughout 4 months of 
storage at -20 ˚C, however, at month 5 the compound displayed a higher MIC of 8 µg/ml. 
Compounds 3 and 4 exhibited strong antimicrobial activity against B. subtils following 6 months 
of storage at -20 ˚C. At the 6 month time-point both compounds exhibited an MIC of only 2 
µg/ml (Figure 11). 
  Fridge storage at 4 ˚C produced similar results to those obtained following storage in the 
freezer (Figure 12). Compound 2 showed significant instability and at month 6 did not inhibit B. 
subtilis even at the highest tested concentration of 16 µg/ml. Compound 1 remained stable until 4 
months, but showed a significant reduction in activity at month 5 and 6. Compounds 3 and 4 
remained relatively stable throughout the test period. 
  Compound 2 appeared to be the least stable of the compounds when stored at room 
temperature without light exposure. It exhibited an MIC of 8 µg/ml against B. subtilis at month 2 
and 3, which increased to 16 µg/ml by month 4. At 6 months time the compound no longer 
displayed bioactivity against the bacteria even at the highest tested concentration of 16 µg/ml. 
Compound 1 was the second least stable of the compounds stored in this environment. At month 
5, compound 1 displayed an MIC of 8 µg/ml against B. subtilis, which rose to 16 µg/ml at month 
6. Compound 3 was able to retain its bioactivity following 6 months of storage at room 
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temperature without exposure to light. Following the 6 month storage period, the mixture of 
compounds exhibited the low MIC of 2 µg/ml (Figure 13). Finally, compound 4 showed it is 
susceptible to higher storage temperatures as it displayed an increased MIC of 4 µg/ml at month 
5 and 6.  
  As displayed in Figure 14, the activity of the isolated compounds was decreased 
following storage at room temperature with light exposure. Compound 2 displayed an MIC of 16 
µg/ml against B. subtilis following only 4 months of storage. Compound 1 had lost its inhibitory 
activity against B. subtilis at all tested concentrations by 6 months time. Compound 3 showed the 
most stability, exhibiting an MIC of 4 µg/ml following the test period. Finally, compound 4 
displayed an MIC of 8 µg/ml following 6 months of storage at room temperature with exposure 
to light.  
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Figure 10 Minimum inhibitory concentration (MIC) of heat treated compounds against B. 
subtilis bacteria.  
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Figure 11 Minimum inhibitory concentration (MIC) of compounds stored at -20 ˚C against B. 
subtilis bacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
0 
2 
4 
6 
8 
10 
12 
14 
16 
0 1 2 3 4 5 6 
M
IC
 µ
g/
m
l)
 
Storage Time (Months) 
Compound 1 
Compound 2 
Compound 3 
Compound 4 
80 
 
 
Figure 12 Minimum inhibitory concentration (MIC) of compounds stored at 4 ˚C against B. 
subtilis bacteria. 
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Figure 13 Minimum inhibitory concentration (MIC) of compounds stored at room temperature 
without light exposure against B. subtilis bacteria. 
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Figure 14 Minimum inhibitory concentration (MIC) of compounds stored at room temperature 
with light exposure against B. subtilis bacteria. 
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Discussion 
 
  Thermal Stress Testing - Compounds isolated from plant and marine organisms were 
subjected to various levels of heat treatment. Only compound 2 showed a significantly decreased 
activity level at human body temperature of 37 ˚C. This compound may not be stable enough to 
be used as a pharmaceutical agent, as it may not provide the desired effect in such circumstances. 
Furthermore, compound 2 was not able to inhibit the B. subtilis bacteria following heat treatment 
at 80 ˚C even at the highest tested concentration of 16 µg/ml. Thermal treatment of antimicrobial 
agents which resulted in a reduction of antimicrobial activity suggests compound degradation 
[91]. The potential applications of compound 2 are limited as the results of the thermal stress test 
lead to the fact that compound 2 is unlikely to hold up to long-term stability tested even at lower 
temperatures.  
  The remaining compounds maintained a high level of activity following heat treatment 
at temperatures up to 121 ˚C. This proves that these compounds may have potential application 
as pharmaceutical agents, or food preservatives. The concentration used may need to be 
increased to compensate for the 8-fold reduction of activity of compound 4 at 121 ˚C. The results 
also lead to the hypothesis that compounds 2 and 3 are the most likely to remain active following 
more long-term shelf stability testing.  
  Effect of pH Treatment - The compounds were originally dissolved in DMSO to produce 
the stock solution which was stored in the freezer. Stock solutions were dried under the fume 
hood overnight, so that the compounds were able to be rehydrated in buffer and access the effect 
of the varying pH level on the efficacy of the antimicrobial agent. Unfortunately, dissolving the 
compounds directly in buffer was not possible. The results prove that the compounds had 
significant loss of activity following the preparation of the samples. This is apparent by the fact 
84 
 
 
that none of the compounds performed as expected even when only water was added to the 
CAMHB broth. There are two possible explanations for the results that were obtained. The first 
explanation is that the active compounds were volatile and lost activity during the drying of the 
stock solution. A second possibility is that the active compounds bound to the vial when the 
DMSO was evaporated, and when buffer was added, the active compound did not become 
incorporated into the solution, even with vortex mixing. Compounds 2 and 4 did show inhibitory 
activity at the low concentration of 1 µg/ml at a few specific pH levels, however, there is not 
sufficient data to support any findings on the effect of pH on the isolated active compounds. It is 
most probable that buffers of pH 9 and 10 were the most successful at dissolving compounds 2 
and 4. Although DMSO and distilled water have similar pH levels, DMSO is an aprotic solvent 
while water represents a protic solvent and has a higher polarity. These differences are likely 
responsible for the unexpected results. 
  Storage Conditions - As expected, all the compounds were found to be susceptible to 
variations in storage conditions. Compound 1 displayed an increased stability when stored at 
fridge or freezer temperature. Furthermore, exposure to light had an effect on the bioactivity of 
the compound. The applicability of this compound is limited as it is not shelf-stable for an 
extended period of time.  
  Compound 2 was the least stable of the compounds examined. In all storage conditions 
the compound displayed significant loss of bioactivity against B. subtilis. Only when stored at -
20 ˚C did the compound show any inhibitory activity at month 6 (MIC of 16 µg/ml). This 
compound has shown instability in all tests, and would not be chosen for further development for 
this reason. 
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  The mixture of compounds present in compound 3 retained activity following 6 months 
of storage in all of the tested environments. This compound is the most likely to be shelf-stable 
for an extended period of time.  
  Compound 4 was the second most stable of all the compounds tested. It retained 
inhibitory activity in all tested environments. This compound was susceptible to light, so opaque 
packaging would be recommended to increase the shelf-life of this product.  
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CHAPTER 5: CYTOTOXICITY OF ISOLATED COMPOUNDS 
Introduction 
 
 Plants have been eaten and used in traditional medicine for centuries. This leads many to 
believe that all compounds derived from natural sources are safe for human consumption. 
However, an isolated active compound requires testing to ensure it is safe in its purified form, 
and at the level required to inhibit the bacterial growth. Plant research is currently separated into 
ethnopharmacology (ex. medicinal herbs) and toxicology (ex. poisonous plants). Both types of 
research have led to the production of drugs and lead compounds [34].  Compounds are often 
tested using an in vitro cell culture system and cytotoxicity is determined by the effect of the 
compound on the cell growth rate [92]. MTS assay represents a well established measurement 
system for cytotoxicity.  The assay relies on the conversion of a tetrazolium salt into a coloured 
formazan product by mitochondrial activity of viable cells. The amount of living cells in the 
culture is directly proportional to the amount of formazan produced and is measured at 492 nm 
[93]. The assay is known to produce precise results in a timely manner [94].   
Materials and Methods 
 
 To fulfill this aim, the cytotoxicity of isolated active compounds was determined by 
MTS assay using mouse embryonic fibroblast (MEF) cell line, NIH 3T3 obtained from ATCC. 
MTS assay was conducted as previously described [95]. Active compounds were dissolved in 
DMSO to prepare a stock solution with a concentration of 1 mg/ml.  The stock solution was 
diluted in sterile distilled water to obtain samples with a concentration of 250 µg/ml. The NIH 
3T3 cells (5 x 10
3
) were seeded in a 96-well culture plate and after overnight incubation the 
medium was removed and replaced with a fresh medium containing isolated active compounds at 
50 µ/ml, 25 µg/ml. Controls were included that did not contain any test substance (1:3 water: 
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DMSO or 1:7 water: DMSO). After 72 h of incubation, 20 µl of CellTiter 96 AQueous One 
Solution Reagent (Promega, Madison, WI) was added to each well. After 2 h incubation at 37 °C 
in a humidified, 5 % CO2 atmosphere, the absorbance at 485 nm was recorded on an ELx800 
plate reader (Bio-Tek, Winooski, VT). The untreated control of every experiment was defined as 
100% proliferation and the values of the antimicrobial-treated cultures were calculated in relation 
to the control. Each variant of the experiment was performed in octuplet.  
Results 
 
  Cell proliferation studies of the isolated active compounds showed varying degrees of 
cytotoxicity using the NIH 3T3 MEF cell line. At a concentration of 25 µg/ml, all compounds 
exhibited significant cytotoxicity (Table 16). Compounds 1 and 4 displayed 40.5 and 41.6% 
proliferation, respectively. The MEF cell line was further diminished by treatment with 
compounds 2 and 3 at 25 µg/ml, resulting in only 9.8% and 5.4% cell proliferation, respectively. 
  When the concentration of isolated active compounds was increased to 50 µg/ml, the 
results were more pronounced. The MEF cell line treated with compounds at 50 µg/ml resulted 
in almost complete obliteration of cell viability. Cell proliferation was between 0.32% and 3.9% 
following treatment with isolated active compounds 1-4 at a concentration of 50 µg/ml (Table 
17).  
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Figure 15 MTS assay of NIH 3T3 cell proliferation caused by isolated active compounds at a 
concentration of 25 µg/ml.  
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Table 16 MTS assay of NIH 3T3 cell proliferation caused by isolated active compounds at a 
concentration of 50 µg/ml.  
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Discussion 
 
  All isolated compounds were found to be cytotoxic to the mouse embryonic fibroblast 
(MEF) cell line, NIH 3T3. Although this has important implications in the applicability of the 
compounds and their further development, it is not uncommon for the current pharmaceutical 
antibiotics to be cytotoxic to normal human cells. Researchers tested the cytotoxicity of common 
antibiotics ciprofloxacin, moxifloxacin, erythromycin against primary human osteoblasts. The 
commonly used antibiotics were found to display cytotoxicity, however higher concentrations 
were tested (400 µg/ml) [96]. Researchers often determine the specific mechanism by which an 
agent exerts cytotoxicity. After isolating the cause of the cytotoxicity, it is possible to modify the 
structure of the compound to remove its cytotoxic effect, while keeping its desirable 
antimicrobial activity. This process of molecular modification is a step in the drug development 
process which is often carried out when a lead compound with exceptional bioactivity is 
discovered to exhibit cytotoxicity [97].   
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS 
The ongoing development of resistance of pathogenic bacteria to antibiotics represents a 
major threat to public health. The issue is exacerbated by the fact that new drugs rarely succeed 
in being fully developed and made available to consumers [98]. Natural products have seemingly 
endless chemical diversity and are central to current pharmaceutical development [98]. The 
primary aim of this project was to identify and characterize components of plant and marine 
extracts with inhibitory activity against those bacterial species which are considered high priority 
due to antimicrobial resistance and high incidence of occurrence.  
 In this study, extracts of plant and marine organisms were screened for antimicrobial 
activity against a number of high priority bacterial pathogens. Screening led to the identification 
of four extracts with superior, broad-spectrum, antimicrobial activity. The extracts chosen were 
from M. africana, P. papyracea, M. unguiculata, and D. herbacea; a plant organism and three 
marine sponges. Bioassay-guided fractionation of the extracts led to the isolation of the active 
component in each extract. Extracts from M. africana, P. papyracea, and D. herbacea each led 
to the isolation and identification of a single, previously known compound; compounds 1, 2, and 
4, respectively. The fractionation of the marine sponge M. unguiculata led to the isolation of a 
mixture of compounds, containing one previously unknown compound, monanchocidin F. All of 
the isolated active compounds displayed antimicrobial activity considered potentially useful for 
pharmaceutical development, ie. MIC’s in the range of 0.02-10 µg/ml [98]. While all the 
compounds displayed antimicrobial activity on a variety of gram-positive and gram-negative 
bacteria, only the mixture of compounds in compound 3 was able to inhibit the growth of three 
species of gram-negative enterobaceriaceae E. coli 0157h7, K. pneumoniae, and S. typhimurium. 
After examining the ability of the isolated compounds to retain their antimicrobial effect 
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following thermal stress, and storage in various environments, it was found that compounds 3 
and 4 were very stable, compound 1 was intermediate, and compound 2 was highly unstable. 
Finally, MTS assay proved that all the compounds were cytotoxic to the mouse embryonic cell 
line NIH 3T3. 
 In some cases, the extracts and isolated active compounds displayed similar levels of 
inhibitory activity against bacterial species. The loss of bioactivity is a common setback involved 
in isolation of bioactive components of extracts. Compounds 2 and 3 displayed inhibitory 
activity similar to the original extract of P. papyracea and M. unguiculata, respectively. Stability 
testing led to the conclusion that compound 2 is highly instable in nature. It is most likely that 
the degradation of compound 2 led to its decreased antimicrobial activity when compared with 
the original extract. For this reason, it would not be advisable to continue development of 
compound 2 as a natural antimicrobial. In the case of the mixture of compounds in compound 3, 
this mixture of compounds performed very well in stability studies and withstood environmental 
factors of degradation. This leads to the conclusions that the M. unguiculata extract may contain 
other antimicrobial components that were passed over during fractionation. It is likely that the 
mixture of compounds in compound 3, although highly active on their own, may work 
synergistically with other compounds in the extract. As compound 3 includes a previously 
undiscovered compound, which has been shown to be possess strong antimicrobial activity and 
stability, future directions for this work should focus heavily on the M. unguiculata extract. A 
small sample of extract was obtained for the purpose of this work. For future work, a larger 
sample of M. unguiculata may be obtained. This sample may be extracted and fractionated in a 
similar fashion to identify and isolate each active compound within the extract. Finally, the 
compounds may be combined in varying ratios to increase their antimicrobial activity. Although 
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compound 3 exhibited inhibitory activity on all of the bacterial species included in this study, 
further development should focus on its activity against the gram-negative enterobaceriaceae, E. 
coli 0157: H7, K. pneumoniae, and S. typhimurium. Further research should focus on elucidating 
the mechanism responsible for the antimicrobial activity of these compounds, as well as the 
mode of action responsible for their cytotoxicity. Molecular modification may be employed to 
further develop the lead compound. 
 Future work should also focus on the development of compound 1 as a replacement for 
the pharmaceutical agents used to control the bacterial species A. baumannii, and L. 
monocytogenes. Compound 1 displayed high antimicrobial activity against these two high 
priority pathogens which has not been described previously.  
  Compound 4 deserves further development as a natural antimicrobial as well. It could be 
developed as a replacement for currently used antibiotics for B. subtilis, C. Jejuni, P. aeruginosa, 
S. aureus, and S. pneumoniae. Compound 4 has potential as an antibmicrobial as it was highly 
active against a broad spectrum of bacterial species, it was a lead compound, displaying lower 
MIC’s than the original extract, and it was found to be highly stable to stress and environmental 
factors. Future research should focus on the mechanism of action of the oxy-polyhalogenated 
diphenyl ether isolated from Dysidea herbacea as well as the mechanisms responsible for it’s 
cytotoxicity against the MEF cell line. Chemical modification of this compound could lead to 
pharmaceutical development.  
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 Antibiotic agents have been found to have a limited lifespan due to the ability of 
microrganisms to develop antimicrobial resistance. In this study a number extracts of plant and 
marine organisms were evaluated for their antimicrobial activity against a number of high 
priority pathogens. Bioassay-guided fractionation of four extracts led to the identification of 
compounds with inhibitory activity; including one previously unknown compound. Compounds 
were evaluated through a variety of techniques including broth microdilution assay to determine 
each compound’s MIC and MBC. The majority of the compounds showed antimicrobial activity 
equal to, if not better than, the commonly used antimicrobial drugs. The ability of compounds to 
withstand environmental stress and storage were explored with only one compound showing 
significant instability. Finally MTS assay showed that cell proliferation was decreased when 
mouse embryonic fibroblast cells, NIH 3T3 were treated with the compounds, proving they are 
cytotoxic to varying degrees. 
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